98 related articles for article (PubMed ID: 24590864)
1. Selective inhibition of mutant Ras protein through covalent binding.
Rudolph J; Stokoe D
Angew Chem Int Ed Engl; 2014 Apr; 53(15):3777-9. PubMed ID: 24590864
[TBL] [Abstract][Full Text] [Related]
2. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Lim SM; Westover KD; Ficarro SB; Harrison RA; Choi HG; Pacold ME; Carrasco M; Hunter J; Kim ND; Xie T; Sim T; Jänne PA; Meyerson M; Marto JA; Engen JR; Gray NS
Angew Chem Int Ed Engl; 2014 Jan; 53(1):199-204. PubMed ID: 24259466
[TBL] [Abstract][Full Text] [Related]
4. High-frequency 94 GHz ENDOR characterization of the metal binding site in wild-type Ras x GDP and its oncogenic mutant G12V in frozen solution.
Bennati M; Hertel MM; Fritscher J; Prisner TF; Weiden N; Hofweber R; Spörner M; Horn G; Kalbitzer HR
Biochemistry; 2006 Jan; 45(1):42-50. PubMed ID: 16388579
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras.
Farin K; Schokoroy S; Haklai R; Cohen-Or I; Elad-Sfadia G; Reyes-Reyes ME; Bates PJ; Cox AD; Kloog Y; Pinkas-Kramarski R
Cancer Res; 2011 Mar; 71(6):2140-51. PubMed ID: 21257709
[TBL] [Abstract][Full Text] [Related]
6. An unexpected new role of mutant Ras: perturbation of human embryonic development.
Kratz CP; Niemeyer CM; Zenker M
J Mol Med (Berl); 2007 Mar; 85(3):227-35. PubMed ID: 17211612
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
8. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].
Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J
Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
Khan I; Rhett JM; O'Bryan JP
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
[TBL] [Abstract][Full Text] [Related]
10. Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics.
Yoo DY; Hauser AD; Joy ST; Bar-Sagi D; Arora PS
ACS Chem Biol; 2020 Jun; 15(6):1604-1612. PubMed ID: 32378881
[TBL] [Abstract][Full Text] [Related]
11. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
[TBL] [Abstract][Full Text] [Related]
12. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations.
Burge RA; Hobbs GA
Adv Cancer Res; 2022; 153():29-61. PubMed ID: 35101234
[TBL] [Abstract][Full Text] [Related]
13. Ras inhibition via direct Ras binding--is there a path forward?
Wang W; Fang G; Rudolph J
Bioorg Med Chem Lett; 2012 Sep; 22(18):5766-76. PubMed ID: 22902659
[TBL] [Abstract][Full Text] [Related]
14. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Oda K
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
[TBL] [Abstract][Full Text] [Related]
15. Ras signaling and therapies.
Young A; Lyons J; Miller AL; Phan VT; Alarcón IR; McCormick F
Adv Cancer Res; 2009; 102():1-17. PubMed ID: 19595305
[TBL] [Abstract][Full Text] [Related]
16. [Oncogenes and tumor suppressor genes in the signal transduction pathways of growth factors].
Buday L
Orv Hetil; 1994 Nov; 135(47):2579-84. PubMed ID: 7824256
[TBL] [Abstract][Full Text] [Related]
17. Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange.
Nnadi CI; Jenkins ML; Gentile DR; Bateman LA; Zaidman D; Balius TE; Nomura DK; Burke JE; Shokat KM; London N
J Chem Inf Model; 2018 Feb; 58(2):464-471. PubMed ID: 29320178
[TBL] [Abstract][Full Text] [Related]
18. Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated Ras protein.
Rosnizeck IC; Spoerner M; Harsch T; Kreitner S; Filchtinski D; Herrmann C; Engel D; König B; Kalbitzer HR
Angew Chem Int Ed Engl; 2012 Oct; 51(42):10647-51. PubMed ID: 22996816
[TBL] [Abstract][Full Text] [Related]
19. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.
Villalonga P; López-Alcalá C; Bosch M; Chiloeches A; Rocamora N; Gil J; Marais R; Marshall CJ; Bachs O; Agell N
Mol Cell Biol; 2001 Nov; 21(21):7345-54. PubMed ID: 11585916
[TBL] [Abstract][Full Text] [Related]
20. K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.
Ma Y; Guo FC; Wang W; Shi HS; Li D; Wang YS
Mol Med Rep; 2013 Sep; 8(3):763-8. PubMed ID: 23877793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
